// App-Quantinova.ai

3264 : Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models

Researchers

Presenter

  • Yusuke Adachi

Principal Investigators

  • Masahiro Matsuki

  • Atsumi Yamaguchi

  • Yoichi Ozawa

  • Kiyochi Okamoto

  • Kaoru Mitsuhashi

  • Takayuki Kimura

  • Taisuke Hoshi

  • Osamu Tohyama

  • Kenji Tai

  • Makoto Ogo

  • Yasuhiro Funahashi

  • Junji Matsui

Medical Centers

  • Eisai Co., Ltd., Tsukuba-city, Japan.

Locations

  • Japan

Companies

  • Eisai Co., Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Thyroid Cancer

  • Solid malignancies

Biomarkers

  • Platelet derived growth factor

  • Platelet-derived growth factor receptor

  • Hepatocyte growth factor receptor

  • Ret Proto-Oncogene

  • Fibroblast growth factor receptor 1

  • Fms related tyrosine kinase 1

  • Fms related tyrosine kinase 4

  • Kinase Insert Domain Receptor

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Vascular endothelial growth factor A

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Everolimus

  • Lenvatinib

  • L-Tyrosine

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved